Trial Profile
An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational
- Acronyms ALITHIOS
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 17 Apr 2024 According to a Novartis Media Release, will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting held in Denver, Colorado and virtually on April 13-18, 2024.
- 17 Apr 2024 Results presented in a Novartis Media Release.
- 13 Oct 2023 Results assessing the effect of ofatumumab on serum IgG/IgM levels up to 5 years during the core and open-label extension studies (ASCLEPIOS I/II, APOLITOS, APLIOS & ALITHIOS) presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.